scholarly journals Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

2019 ◽  
Vol 111 (3) ◽  
pp. 245-255 ◽  
Author(s):  
Joseph M Unger ◽  
Riha Vaidya ◽  
Dawn L Hershman ◽  
Lori M Minasian ◽  
Mark E Fleury
Author(s):  
Kathleen B. Cartmell ◽  
Heather S. Bonilha ◽  
Kit N. Simpson ◽  
Marvella E. Ford ◽  
Debbie C. Bryant ◽  
...  

Author(s):  
Joseph M Unger ◽  
Dawn L Hershman ◽  
Cathee Till ◽  
Lori M Minasian ◽  
Raymond U Osarogiagbon ◽  
...  

Abstract Background Patient participation in clinical trials is vital for knowledge advancement and outcomes improvement. Few adult cancer patients participate in trials. Although patient   decision-making about trial participation has been frequently examined, the participation rate for patients actually offered a trial is unknown. Methods A systematic review and meta-analysis using 3 major search engines was undertaken. We identified studies from January 1, 2000, to January 1, 2020, that examined clinical trial participation in the United States. Studies must have specified the numbers of patients offered a trial and the number enrolled. A random effects model of proportions was used. All statistical tests were 2-sided. Results We identified 35 studies (30 about treatment trials and 5 about cancer control trials) among which 9759 patients were offered trial participation. Overall, 55.0% (95% confidence interval [CI] = 49.4% to 60.5%) of patients agreed to enroll. Participation rates did not differ between treatment (55.0%, 95% CI = 48.9% to 60.9%) and cancer control trials (55.3%, 95% CI = 38.9% to 71.1%; P = .98). Black patients participated at similar rates (58.4%, 95% CI = 46.8% to 69.7%) compared with White patients (55.1%, 95% CI = 44.3% to 65.6%; P = .88). The main reasons for nonparticipation were treatment choice or lack of interest. Conclusions More than half of all cancer patients offered a clinical trial do participate. These findings upend several conventional beliefs about cancer clinical trial participation, including that Black patients are less likely to agree to participate and that patient decision-making is the primary barrier to participation. Policies and interventions to improve clinical trial participation should focus more on modifiable systemic structural and clinical barriers, such as improving access to available trials and broadening eligibility criteria.


Cancer ◽  
2017 ◽  
Vol 123 (15) ◽  
pp. 2893-2900 ◽  
Author(s):  
Christine B. Mackay ◽  
Kaitlyn R. Antonelli ◽  
Suanna S. Bruinooge ◽  
Jarron M. Saint Onge ◽  
Shellie D. Ellis

2020 ◽  
Vol 159 ◽  
pp. 293-294
Author(s):  
N.L. Rezvani ◽  
O.E. Gilbert ◽  
C. Smith ◽  
A.G. Chapple ◽  
N. Nair ◽  
...  

2019 ◽  
Vol 24 (8) ◽  
pp. 1048-1055 ◽  
Author(s):  
Ryan D. Nipp ◽  
Hang Lee ◽  
Emily Gorton ◽  
Morgan Lichtenstein ◽  
Salome Kuchukhidze ◽  
...  

2021 ◽  
Vol 4 (7) ◽  
pp. e2118433
Author(s):  
Joseph M. Unger ◽  
Hong Xiao ◽  
Michael LeBlanc ◽  
Dawn L. Hershman ◽  
Charles D. Blanke

Sign in / Sign up

Export Citation Format

Share Document